<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02708875</url>
  </required_header>
  <id_info>
    <org_study_id>H14086</org_study_id>
    <nct_id>NCT02708875</nct_id>
  </id_info>
  <brief_title>Microvascular Insulin Resistance and Mixed Meal Challenge</brief_title>
  <official_title>Microvascular Insulin Resistance and Mixed Meal Challenge</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menzies Institute for Medical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deakin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Menzies Institute for Medical Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin resistance (or pre-diabetes) is diagnosed using the oral glucose tolerance test.
      However, high blood glucose levels during this test may adversely impact on microvascular
      function. Investigators will determine whether a liquid mixed meal challenge (from
      carbohydrate, protein and fat) is a more appropriate test for assessing microvascular-derived
      insulin resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After consuming a meal, 80% of glucose is disposed in skeletal muscle. Our research group has
      demonstrated that microvascular blood flow in skeletal muscle plays an integral role in this
      process. Physiological doses of insulin stimulate microvascular blood flow, and that this
      increase is associated with enhanced glucose uptake by muscle. This microvascular action of
      insulin is lost during insulin resistance and type 2 diabetes.

      The oral glucose tolerance test (GTT) is the gold standard for assessing insulin resistance
      and pre-diabetes and is used world-wide. However high blood glucose levels following a
      glucose load may adversely impact on microvascular function. The aim of this project is to
      determine whether a mixed meal challenge (liquid drink consisting of carbohydrate, fat and
      protein) is a better test for assessing microvascular-derived insulin resistance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in muscle microvascular blood flow</measure>
    <time_frame>1 hr</time_frame>
    <description>Microvascular responses will be measured by contrast enhanced ultrasound before and 1hr after each challenge.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in blood glucose levels</measure>
    <time_frame>2 hr</time_frame>
    <description>Blood glucose levels will be measured at 0, 15, 30, 60, 90 and 120 min following each challenge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma insulin levels</measure>
    <time_frame>2hr</time_frame>
    <description>Plasma insulin levels will be measured at 0, 15, 30, 60, 90 and 120 min following each challenge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the respiratory exchange ratio (RER)</measure>
    <time_frame>1 hr</time_frame>
    <description>Changes in RER will be measured by metabolic cart during each challenge.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Mixed Meal Challenge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will consume a liquid mixed meal (~300 calories - fat, carbohydrate, and protein) for monitoring changes in glucose metabolism, plasma insulin and microvascular responses in skeletal muscle over 2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucose Challenge</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will consume a glucose challenge (50g glucose) for monitoring changes in glucose metabolism, plasma insulin and microvascular responses in skeletal muscle over 2 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mixed Meal Challenge</intervention_name>
    <description>Liquid mixed meal (300 calories - fat, carbohydrate, and protein).</description>
    <arm_group_label>Mixed Meal Challenge</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucose Challenge</intervention_name>
    <description>Glucose drink (50g glucose)</description>
    <arm_group_label>Glucose Challenge</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18-65 years.

          -  Normal to overweight (BMI 19-35 kg/m2).

          -  Normotensive (Seated brachial blood pressure &lt;160/100 mmHg).

          -  Considered healthy (HbA1c &lt;6.5 %) or have clinically diagnosed type 2 diabetes.

          -  Either have a parent with T2D, or no family history of type 2 diabetes for two
             generations.

          -  Have given signed informed consent to participate in the study

        Exclusion Criteria:

          -  Age &lt;18 yrs or &gt;65 yrs

          -  Morbidly obese with a BMI â‰¥36 kg/m2

          -  History of myocardial infarction or stroke

          -  History of malignancy within past 5 years (except for non-melanoma skin cancers)

          -  Current smoker

          -  History of severe liver disease

          -  History of drug or alcohol abuse

          -  Elective major surgery during the course of the study

          -  Pregnancy/lactation

          -  Participation or intention to participate in another clinical research study during
             the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle A Keske, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Menzies Institute for Medical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle A Keske, PhD</last_name>
    <phone>+61362262669</phone>
    <email>Michelle.Keske@deakin.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Menzies Institute for Medical Research</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle A Keske, PhD</last_name>
      <phone>+61362262669</phone>
      <email>Michelle.Keske@deakin.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Keske</last_name>
      <phone>+61362262669</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Deakin University</name>
      <address>
        <city>Burwood</city>
        <state>Victoria</state>
        <zip>3125</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle A Keske, PhD</last_name>
      <phone>+613924 68850</phone>
      <email>Michelle.Keske@deakin.edu.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 17, 2016</study_first_submitted>
  <study_first_submitted_qc>March 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2016</study_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Menzies Institute for Medical Research</investigator_affiliation>
    <investigator_full_name>Michelle Keske</investigator_full_name>
    <investigator_title>Senior Research Fellow</investigator_title>
  </responsible_party>
  <keyword>Microvascular</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Mixed Meal</keyword>
  <keyword>Glucose tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

